KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Non-Current Deffered Revenue (2016 - 2022)

Historic Non-Current Deffered Revenue for Emergent BioSolutions (EBS) over the last 11 years, with Q1 2022 value amounting to $5.9 million.

  • Emergent BioSolutions' Non-Current Deffered Revenue fell 8876.19% to $5.9 million in Q1 2022 from the same period last year, while for Mar 2022 it was $5.9 million, marking a year-over-year decrease of 8876.19%. This contributed to the annual value of $4.7 million for FY2021, which is 9153.15% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Non-Current Deffered Revenue of $5.9 million as of Q1 2022, which was down 8876.19% from $4.7 million recorded in Q4 2021.
  • Emergent BioSolutions' Non-Current Deffered Revenue's 5-year high stood at $85.6 million during Q4 2019, with a 5-year trough of $4.7 million in Q4 2021.
  • Moreover, its 5-year median value for Non-Current Deffered Revenue was $62.5 million (2018), whereas its average is $59.0 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Non-Current Deffered Revenue soared by 32748.61% in 2018, and later plummeted by 9153.15% in 2021.
  • Emergent BioSolutions' Non-Current Deffered Revenue (Quarter) stood at $62.5 million in 2018, then skyrocketed by 36.96% to $85.6 million in 2019, then tumbled by 35.16% to $55.5 million in 2020, then plummeted by 91.53% to $4.7 million in 2021, then increased by 25.53% to $5.9 million in 2022.
  • Its last three reported values are $5.9 million in Q1 2022, $4.7 million for Q4 2021, and $45.3 million during Q3 2021.